Scientists at the University of New South Wales in Sydney have achieved a breakthrough that could fundamentally change how gene therapy is delivered to patients. Their new CRISPR technique can switch genes back on without making a single cut to DNA — a development that addresses one of the biggest safety concerns in modern medicine.
The research, published in Nature Communications, also settles a decades-long scientific debate about how genes are silenced in the first place, confirming that tiny chemical markers called methyl groups are not passive bystanders but active anchors that directly suppress gene activity.
From Scissors to Erasers
Traditional CRISPR gene editing works like molecular scissors, cutting DNA at precise locations to disable faulty genes or insert corrected sequences. While revolutionary, this approach carries inherent risks. Every time DNA is cut, there is a chance of unintended mutations — and with them, a small but real risk of cancer.
"Whenever you cut DNA, there's a risk of cancer. And if you're doing a gene therapy for a lifelong disease, that's a bad kind of risk," explained Professor Merlin Crossley, UNSW Deputy Vice-Chancellor and the study's lead author.
The new technique, known as epigenetic editing, takes a fundamentally different approach. Instead of cutting DNA, it targets the chemical modifications — specifically methyl groups — that sit on top of genes and keep them switched off. By removing these molecular anchors, researchers can reactivate silenced genes without altering a single letter of the genetic code.
Settling the Debate
For years, scientists have argued about whether methyl groups on DNA are the cause of gene silencing or merely a consequence of it. Do these chemical tags actively suppress genes, or do they simply accumulate in regions that are already inactive?
The UNSW team, working with colleagues at St. Jude Children's Research Hospital in Memphis, designed an elegant experiment to find out. They removed methyl groups from silenced genes and watched as those genes sprang back to life. When they added the methyl groups back, the genes shut down again.
"We showed very clearly that if you brush the cobwebs off, the gene comes on," said Professor Crossley. "And when we added the methyl groups back, they turned off again. So these compounds aren't cobwebs — they're anchors."
Hope for Sickle Cell Patients
One of the most promising applications is in treating sickle cell disease and related blood disorders. These inherited conditions affect the shape and function of red blood cells, causing severe pain, organ damage, and shortened life expectancy.
The key target is the fetal globin gene, which produces a form of hemoglobin that efficiently carries oxygen before birth but is naturally switched off after. By using epigenetic editing to reactivate this gene in adults with sickle cell disease, scientists could potentially restore healthy oxygen delivery without the risks associated with DNA cutting.
A Safer Future for Medicine
The implications extend well beyond blood disorders. Many diseases involve genes that have been inappropriately silenced. If epigenetic editing proves as versatile as early results suggest, it could offer safer treatments for a wide range of conditions — from genetic disorders to certain cancers where tumor-suppressor genes have been switched off.
The work represents a new chapter in the CRISPR story, one where precision medicine becomes not just more targeted but fundamentally safer for the patients who need it most.
